echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Over the past year, the drug giants who have threw billions of dollars into acquisitions

    Over the past year, the drug giants who have threw billions of dollars into acquisitions

    • Last Update: 2021-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In December 2020, AstraZenecom announced a $39 billion ($255.2 billion) acquisition of Alexion Pharmaceuticals, a rare disease drug developer, the largest acquisition by AstraZene half a year since its inception in 1999.
    Alexion, founded in 1992 to develop drugs for rare diseases and is a global leader in complementary immunity, currently has five products on the market, including the "first-in-class" C5 supplement monoantigen Soliris (ec Ulizumab) and the long-acting C5 supplement inhibitor Ultomiris (ravulizumab) were approved by the FDA in 2007 and 2018, respectively, for the treatment of rare diseases mediated by multiple complement systems.
    Ultomiris contributed nearly $4 billion in sales, including $39.3 million, according to Alexion's 2019 results. With $4.6 billion, Ultomiris ranks 11th in 2019 in antibody drug sales, and while current sales are average, Evaluate Pharma expects sales to reach $3.43 billion in 2024.
    , Alexion currently has more than 20 pipelines in the pipeline, 11 of which are in clinical stages, covering multiple adaptations.
    said the acquisition of Alexion would boost the company's drug development in immunology and rare diseases, while AstraZeneta, which has a one-a-cent revenue from the Chinese market, could reduce its share of the deal.
    $21 billion Gilead buys a biotech company Gilead to start a "buy-to-buy" model in 2020, for $4.9 billion in March 2020 for CD47 antibody drug pioneer Forty Seven, and in June for $275 million for cancer immunotherapy company P After buying a 49.9 percent stake in cancer immunotherapy company Tizona for $300 million in July, Gilead bought U.S. biotech company Immunomedics for about $21 billion in September 2020 for $88 a share in cash.
    's "first-in-class" antibody-coupled drug, Trodelvy (sacituzumab govitecan-hziy), was approved by the U.S. FDA in April 2020 for at least two previously accepted The third-line treatment for adult patients with metastasis triple-negative breast cancer (mTNBC) is the first FDA-approved antibody-coupled drug to treat triple-yin breast cancer and the first antibody-coupled drug to target human nourishment layer cell surface antigen 2 (Trop-2).
    Trodelvy will bring a cornerstone product to Gilead Sciences, broadening and deepening the company's solid tumor pipeline.
    at the same time, insiders had forecast global sales of $1.44 billion by 2024.
    the last month of 2020, Gilead paid another 1.45 billion euros for MYR GmbH, the German biotech company, to bring in the world's first new drug for hepatitis A.
    13.1 billion U.S. dollars, 100 million U.S. Squire cash acquisition of a clinical phase biopharmaceutical company Following the $74 billion acquisition of new base, Shishi Shiguibao once again made a big deal to buy a company.
    In October 2020, Shishi Shiguibao announced a $13.1 billion cash acquisition of myoKardia, a clinical-stage biopharmaceutical company, to reduce its dependence on cancer drugs, a price that set a new record for the size of a clinical-stage pharmaceutical company's acquisition.
    , MyoKardia is a clinical biopharmaceutical company dedicated to the discovery and development of targeted therapies for severe cardiovascular disease.
    through this acquisition, Shishi Shiguibo will acquire its new drug mavacamten, a potential "first-in-class" cardiovascular drug for the treatment of obstructive hypertrophomyopathy (HCM).
    , Mavacamten has been awarded breakthrough therapy and orphan drug qualification by the FDA and is expected to file a listing application with the FDA in the first quarter of 2021.
    said the acquisition provided the company with medium- to long-term growth and was expected to start adding revenue in 2023, with seller analysts estimating Mavacamten generating at least $2.6 billion a year by 2026.
    is also looking forward to evaluating Mavacamten in other adaptations to reach its full potential.
    .5 billion U.S. dollars Johnson and Johnson acquires biopharmaceutical companies with rare immunometric diseases In August 2020, Johnson and Johnson announced a $6.5 billion acquisition of Momenta Pharmaceuticals, a U.S. pharmaceutical company focused on rare immuno-mediated diseases. Pharmaceutical companies, the core product pipeline is the anti-FcRn anti-drug Nipocalimab, which is expected to be an effective treatment for immuno-mediated diseases, which is the main reason for Johnson and Johnson's acquisition of Momomo Pharmaceuticals, nipocalimab is currently in the clinical phase III research and development phase.
    Johnson and Johnson believes this is a clinically proven potential first-class product.
    , Johnson and Johnson now has at least five approved treatments for more than 30 autoimmune diseases that cover children and adults, including its autoimmune disease drug Remicade and the new psoriasis drug Stelara.
    However, both drugs have been affected to varying degrees by peer competition, and for the acquisition, Johnson and Johnson said it would strengthen its subsidiary, Xi'an Jansen Pharmaceuticals, in the field of immuno-mediated diseases, and further develop into the field of autoimmune diseases.
    addition, Janssen Pharmaceuticals will advance nipocalimab's development of adaptations to a variety of autoimmune diseases, including maternal and fetal diseases, neuritis diseases, rheumatism, skin diseases, and autoimmune blood diseases.
    in October 2020, Johnson and Johnson completed its acquisition of Momenta Pharmaceuticals.
    $4 billion Bayer acquired biotech company AskBio in October 2020 for $4 billion, using the company's in-depth gene therapy engineering to acquire Us biotech company Asklepios Bio Pharmaceutical for $4 billion.
    said the acquisition of AskBio was slightly larger than Bayer's all-time acquisition in the pharmaceutical sector.
    it is understood that AskBio is committed to the research, development and manufacture of gene therapies in different therapeutic fields, including preclinical and clinical candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic system diseases.
    the acquisition, Bayer will have full rights to AskBio's adenovirus (AAV) gene therapy platform.
    believes it will have the potential to use AskBio's platform to handle relatively large multigene adaptive disorders and to cover AAV (adeno-related virus) treatments in its CDMO business.
    3.36 billion Sanofi's acquisition of Principia, a U.S. biopharmaceutical company, in August 2020, Sanofi announced the acquisition of Principia Biopharma Inc., a U.S. biopharmaceutical company focused on the development of drugs for multiple sclerosis and a range of autoimmune diseases, with a focus on the development of immunometric disease treatments.
    acquisition, Sanofi will acquire ownership of drugs such as THEP442168, a BTK inhibitor developed by Principia Biopharma to treat multiple sclerosis and other central nervous system diseases.
    said the acquisition would strengthen research and development in areas such as autoimmune and allergic diseases.
    $2.6 billion Nestle's acquisition of Food Allergy Therapy company Aimmune in August 2020, a deal was signed by Sociétés des Produits Nestle, a wholly owned subsidiary of Nestle Health Sciences, and Aimmune Therapeutics, a U.S. food allergy research firm, for an estimated $2.6 billion.
    palforzia, which Nestle is about to obtain, is a protein extracted from peanuts that contains the main allergenic protein.
    The principle of the drug to treat peanut allergy is that by taking a small amount of peanut protein, the patient's immune system gradually desensitizes the peanut protein, making the patient less prone to life-threatening allergic reactions when exposed to peanut ingredients in the future.
    February, Palforzia's use to mitigate possible allergic reactions from accidental exposure to peanuts was approved by the FDA, the first FDA-approved peanut allergy therapy.
    Evaluate Pharma, a foreign media company, expects sales of the drug to reach $1.28 billion by 2024.
    $2.1 billion Norfox acquires Corvidia Therapeutics in June 2020, No.
    core product of Corvidia Therapeutics is ziltivekimab, an all-humanized IL-6 monoclonal antibody with an extended half-life.
    has completed two early clinical trials in patients with chronic kidney disease.
    trial results showed a decrease in the level of C-reactive protein (CRP), an inflammatory marker, in patients treated with low-dose ziltivekimab.
    and Nord believe ziltivekimab has the potential to become a "first-in-class" and "best-in-class" therapy to reduce the risk of major adverse cardiovascular events in high-risk patient populations.
    From the above acquisition, it is not untypical that the giant's acquisition of a company is in fact a bet on one of the company's core products and values its future revenue potential, as Pfizer once acquired Warner Lambert for the heavy drug Atovastatin, which generated $12.9 billion in sales as early as 2006, making it the world's first drug with annual sales of more than $10 billion.
    Again, as the now-famous K-drug, but also after Mercadon from the Netherlands Oganon company to its acquisition, after several twists and turns to discover the potential of PD-1 inhibitors in the clinical, to develop it, only now K drug in Mercedon's revenue-leading position.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.